Pricing Log in Create free account

AC Immune (ACIU) vs Inhibikase Therapeutics, Inc. (IKT)

AC Immune and Inhibikase Therapeutics, Inc. are both Biotechnology companies. AC Immune and Inhibikase Therapeutics, Inc. are of similar size ($255.4M and $249.4M). Inhibikase Therapeutics, Inc. grew revenue faster over the last twelve months: 110.9% against −85.6%. Inhibikase Therapeutics, Inc. has the higher net margin (0.00% vs −1,783.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Inhibikase Therapeutics, Inc. leads on 9 and AC Immune on 5.

Valuation

Metric ACIU IKT Biotechnology median
P/E n/m n/m 8.50
P/S 50.83 1,105.73 9.71
P/B 5.30 1.88 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 31.31 495.30 9.21
Earnings yield (34.31%) (26.06%) (33.15%)
Free cash flow yield (35.48%) (14.80%) (25.50%)

Profitability

Metric ACIU IKT Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (1,745.75%) 0.00% 0.00%
Net margin (1,783.66%) 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (51.96%) (56.36%)
Return on assets 0.00% (48.04%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ACIU IKT Biotechnology median
Revenue growth (TTM) (85.56%) 110.93% 6.02%
EPS growth (last fiscal year) (44.83%) 57.76% 30.26%
Revenue growth, 5-year CAGR (47.84%) (42.21%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACIU IKT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.93 15.82 4.72
Net debt to EBITDA 1.37 3.44 0.96

Dividend

Metric ACIU IKT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ACIU IKT Biotechnology median
Market cap 249.35m 255.35m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack